Clinical trial

Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy in High-risk Prostate Cancer Patients

NCT04565496

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Pembrolizumab Normalized identity: pembrolizumabView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy in High-risk Prostate Cancer Patients

Design: INTERVENTIONAL · Status: WITHDRAWN · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2023-04-10

PhasePHASE2

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Interventions

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

Sponsors & collaborators

IRCCS San Raffaelelead sponsor

Mapped research locations

MilanItaly2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04565496 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.